Center for Immunology and Infectious Diseases, Department of Pathology, Microbiology and Immunology, University of California, Davis, Davis, CA 95616.
Department of Immunobiology, University of Arizona College of Medicine-Tucson, Tucson, AZ 85724.
J Immunol. 2020 Nov 1;205(9):2342-2350. doi: 10.4049/jimmunol.2000839. Epub 2020 Sep 4.
The scale of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) pandemic has thrust immunology into the public spotlight in unprecedented ways. In this article, which is part opinion piece and part review, we argue that the normal cadence by which we discuss science with our colleagues failed to properly convey likelihoods of the immune response to SARS-CoV-2 to the public and the media. As a result, biologically implausible outcomes were given equal weight as the principles set by decades of viral immunology. Unsurprisingly, questionable results and alarmist news media articles have filled the void. We suggest an emphasis on setting expectations based on prior findings while avoiding the overused approach of assuming nothing. After reviewing Ab-mediated immunity after coronavirus and other acute viral infections, we posit that, with few exceptions, the development of protective humoral immunity of more than a year is the norm. Immunity to SARS-CoV-2 is likely to follow the same pattern.
严重急性呼吸综合征冠状病毒 2（SARS-CoV-2）大流行的规模以前所未有的方式将免疫学推向了公众关注的焦点。在这篇既是观点文章又是评论的文章中，我们认为，我们与同事讨论科学的正常节奏未能向公众和媒体正确传达对 SARS-CoV-2 的免疫反应的可能性。因此，不合理的结果与数十年来病毒免疫学的原则一样受到重视。毫不奇怪，有问题的结果和危言耸听的新闻媒体文章填补了空白。我们建议强调基于先前发现设定预期，同时避免过度使用假设什么都没有的方法。在回顾冠状病毒和其他急性病毒感染后的 Ab 介导免疫后，我们假设，除了少数例外，一年以上的保护性体液免疫的发展是常态。对 SARS-CoV-2 的免疫可能遵循相同的模式。
